Acadian Asset Management LLC Decreases Holdings in Brainsway Ltd. Sponsored ADR $BWAY

Acadian Asset Management LLC cut its holdings in shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) by 4.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 336,584 shares of the company’s stock after selling 16,331 shares during the quarter. Acadian Asset Management LLC owned approximately 1.78% of Brainsway worth $3,177,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in BWAY. Valor Management LLC purchased a new stake in Brainsway during the fourth quarter valued at about $19,838,000. ARK Investment Management LLC lifted its holdings in Brainsway by 7.3% during the first quarter. ARK Investment Management LLC now owns 188,328 shares of the company’s stock valued at $1,783,000 after purchasing an additional 12,740 shares during the last quarter. Two Sigma Investments LP lifted its holdings in Brainsway by 2.0% during the fourth quarter. Two Sigma Investments LP now owns 92,755 shares of the company’s stock valued at $875,000 after purchasing an additional 1,786 shares during the last quarter. Huntleigh Advisors Inc. lifted its holdings in Brainsway by 16.7% during the first quarter. Huntleigh Advisors Inc. now owns 73,273 shares of the company’s stock valued at $694,000 after purchasing an additional 10,504 shares during the last quarter. Finally, Eagle Global Advisors LLC purchased a new stake in Brainsway during the first quarter valued at about $590,000. 30.11% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on BWAY. HC Wainwright restated a “buy” rating and issued a $17.00 price objective on shares of Brainsway in a research report on Monday, August 25th. Wall Street Zen upgraded shares of Brainsway from a “hold” rating to a “buy” rating in a research report on Sunday, August 17th. Finally, Northland Securities raised their price objective on shares of Brainsway from $15.00 to $19.00 and gave the company an “outperform” rating in a research report on Thursday, August 14th. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Brainsway presently has an average rating of “Buy” and an average target price of $18.00.

Brainsway Stock Performance

Shares of BWAY stock opened at $15.10 on Tuesday. Brainsway Ltd. Sponsored ADR has a fifty-two week low of $7.84 and a fifty-two week high of $16.25. The stock has a 50 day moving average price of $13.51 and a two-hundred day moving average price of $11.25. The company has a market capitalization of $285.42 million, a P/E ratio of 58.08 and a beta of 1.34.

Brainsway (NASDAQ:BWAY) last posted its earnings results on Wednesday, August 13th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.03. Brainsway had a return on equity of 8.97% and a net margin of 11.60%.The firm had revenue of $12.63 million for the quarter, compared to analysts’ expectations of $12.34 million. Brainsway has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Brainsway Ltd. Sponsored ADR will post 0.08 earnings per share for the current year.

Brainsway Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.